Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Diabeloop WP7 : Crossover Evaluation of the Safety and the Efficacy of Artificial Pancreas Diabeloop (WP7) (WP7)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02987556
Recruitment Status : Completed
First Posted : December 9, 2016
Last Update Posted : February 1, 2019
Sponsor:
Information provided by (Responsible Party):
Centre d’Etudes et de Recherche pour l’Intensification du Traitement du Diabète

Brief Summary:

The study will be conducted in crossover trial, with two 12-weeks periods separated by a Wash-out period of at least one month. According to randomization ,patients will be provided with either Diabeloop system or the usual system.

Patients will be trained for the use of blood glucose meter, of external Insulin Pump and Diabeloop system.

In both treatment periods, the same blood glucose meter will be used throughout the duration of the study.

In two centers (Centre Hospitalier Sud-Francilien and Grenoble), a pre-study will be performed during four weeks to improve the efficacy of Diabeloop system with data collection, to test the manual settings by health care providers and patients and to check the good-working of the follow-up platform.


Condition or disease Intervention/treatment Phase
Closed Loop Diabetes Mellitus, Type 1 Device: Continuous Glucose Monitoring Device: External Insulin Pump Other: telemdecine Device: The Diabeloop Software (Model predictive control) Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 71 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Intervention Model Description: Closed loop vs. Open loop,
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Crossover Evaluation of the Safety and the Efficacy of Artificial Pancreas Diabeloop for Three Months at Home in Comparison With Conventional Treatment by External Insulin Pump in Patients With Type 1 Diabetes.
Actual Study Start Date : March 30, 2017
Actual Primary Completion Date : August 28, 2018
Actual Study Completion Date : August 28, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Diabetes Type 1
Drug Information available for: Insulin

Arm Intervention/treatment
Active Comparator: Usual System (open-loop)
In open loop, patients will be provided with an Continuous Glucose Monitoring (CGM) and an external insulin pump programmed with its usual treatment previously prescribed by its physician.
Device: Continuous Glucose Monitoring
Collection of glucose data

Device: External Insulin Pump
insulin delivery

Experimental: DIABELOOP System (closed-loop)
In the closed-loop, patients will be provided with the Diabeloop system consisting of insulin pump Cellnovo or Kaleido driven by remote control augmented by Diabeloop software and connected to the CGM Prescription of insulin doses proposed by a predictive algorithm.
Device: Continuous Glucose Monitoring
Collection of glucose data

Device: External Insulin Pump
insulin delivery

Other: telemdecine
Remote follow up by care health providers team

Device: The Diabeloop Software (Model predictive control)
Diabeloop is a Closed-loop (CL) system with a Model Predictive Control (MPC) algorithm reinforced by a decisional matrix, uploaded on a dedicated android smartphone linked to Dexcom CGM and a Cellnovo or Kaleido insulin patch-pump. The Diabeloop software calculates the insulin dose according to the patient's needs.




Primary Outcome Measures :
  1. Percentage of time spent in the tight glycemic control area 70-180 mg/dl continuously measured for 12 weeks [ Time Frame: For 12 weeks ]
    measurement of glucose by CGM


Secondary Outcome Measures :
  1. Percentage of time spent in the glycemic range 70-180 mg/dl, 80-140 mg/dl and in blood glucose >180 mg/dL during nights and during 24 hours for 12 weeks [ Time Frame: During 24 hours for 12 weeks ]
    measurement of glucose by CGM

  2. Measurement of HbA1c at the onset and at the end of each period of treatment [ Time Frame: During 12 weeks for each period of treatment ]
    Dosage of HbA1c every 3 months

  3. Average blood glucose levels throughout the full period [ Time Frame: During 12 weeks for each period of treatment ]
    measurement of glucose by CGM

  4. Calculated risks of hypo- and hyperglycemia (LBGI, HBGI) throughout the full period during 12 weeks [ Time Frame: Throughout the full period during 12 weeks ]
    measurement of glucose by CGM

  5. Total supplies of insulin during tests [ Time Frame: During 12 weeks for each period ]
    total basal and bolus by 24h

  6. Number of hyper-glycemic events defined by American Diabetes Association (ADA) : severe hyperglycemia > 360 mg/dl (20 mmol/l) measured by CGM or significant ketose (acetonemia > 3 mmol/l) [ Time Frame: During 12 weeks for each period ]
    measurement of glucose by CGM

  7. Number of hypoglycemic events, defined by any threshold crossing 60 mg/dl ( 3,33 mmol/l); 70 mg/dl (3,9 mmol/l) and < 54 mg/dl (3 mmol/l) measured by the CGM [ Time Frame: During 12 weeks for each period ]
    measurement of glucose by CGM

  8. Measuring the oral carbohydrates intake during the last week of each period of treatment [ Time Frame: During 24 hours for one week before the end of each period of treatment ]
    data collected on a booklet

  9. Number of technical problems causing interruptions of the closed loop [ Time Frame: During 12 weeks for the closed loop period ]
    technical incidents data collected during the study

  10. Percentage of time spent in good-working mode during the closed loop period [ Time Frame: During 12 weeks for the closed loop period ]
    measurement of glucose by CGM

  11. For the use and the acceptance, a satisfaction survey will be done on the daily management of diabetes, the modification of daily life with the system dan the fear of hypoglycemia [ Time Frame: During 12 weeks at the end of each period of treatment ]
    DTSQ satisfaction questionnaire, with scale from 6 to 0 where 0 is the worth and 6 the best outcome.

  12. Percentage of time spent in blood glucose <70 mg/dl continuously measured for 12 weeks [ Time Frame: For 12 weeks ]
    measurement of glucose by CGM



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Type 1 diabetic patient for at least two years
  • Patient treated by external insulin pump for at least 6 months
  • Patient with HbA1c ≤ 10%; dosage of less than 4 months done in analysis laboratory medical or equivalent.
  • Patient requiring a daily dose of insulin ≤ 50 units
  • Patient domiciled in an area with Global System for Mobile Communication (GSM)
  • Not isolated patient, not living alone, or having a person "resource" living nearby and having a phone and the key of its place of residence
  • Patient not envisaging a journey outside France during the "closed-loop" period
  • Patient aged over 18 years
  • Patient affiliated to Social Security
  • Patient who agreed to participate in the study and who signed an informed consent

Exclusion Criteria:

  • Patient with any serious illness that may impair study participation
  • Patient having a treatment known to have a significant interference on the glycemia.
  • Patient enjoying a measure of legal protection
  • Pregnant woman or likely to be

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02987556


Locations
Layout table for location information
France
Centre Hospitalier Universitaire Jean Minjoz
Besancon, France, 25030
Centre Hospitalier Universitaire
Caen, France, 14033
Centre Hospitalier Sud-Francilien
Corbeil-Essonnes, France, 91100
Centre Hospitalier Universitaire
Grenoble, France, 38700
Centre Hospitalier Universitaire
Lyon, France, 69000
Centre Hospitalier Universitaire
Marseille, France, 13000
Centre Hospitalier Universitaire
Montpellier, France, 34295
Centre Hospitalier Universitaire
Nancy, France, 54000
Centre Hospitalier Universitaire
Nantes, France, 44000
Centre Hospitalier Universitaire
Reims, France, 51100
Centre Hospitalier Universitaire
Strasbourg, France, 67000
Centre Hospitalier Universitaire
Toulouse, France, 31400
Sponsors and Collaborators
Centre d’Etudes et de Recherche pour l’Intensification du Traitement du Diabète

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Centre d’Etudes et de Recherche pour l’Intensification du Traitement du Diabète
ClinicalTrials.gov Identifier: NCT02987556     History of Changes
Other Study ID Numbers: 2016-A01198-43
First Posted: December 9, 2016    Key Record Dates
Last Update Posted: February 1, 2019
Last Verified: May 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 1
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases
Insulin
Insulin, Globin Zinc
Pancrelipase
Hypoglycemic Agents
Physiological Effects of Drugs
Gastrointestinal Agents